Therefore, the objective of this study was to evaluate the performance of the fluorescent photosensitizer IRDye700DX conjugated to the anti‐epidermal growth factor receptor (EGFR) monoclonal antibody panitumumab (panitumumab‐IRDye700DX; Pan‐IR700) as a PIT agent to eliminate microscopic residual disease in a wound bed following incomplete surgical resection in a model of SCCHN. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.